J Korean Med Sci.  2024 Sep;39(35):e245. 10.3346/jkms.2024.39.e245.

Varicella Vaccine Safety: Absence of Evidence Is Not Evidence of Absence

• Lee J

• KMID: 2559196
• DOI: http://doi.org/10.3346/jkms.2024.39.e245

Reference

1. Korea Disease Control and Prevention Agency, Ministry of Food and Drug Safety. Announcement of joint public-private investigation results on the safety of varicella vaccine. Updated 2024. Accessed July 11, 2024. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=725423&cg_code=&act=view&nPage=1&newsField= .

2. Korea Disease Control and Prevention Agency. The KDCA had not disclosed any details regarding varicella vaccine safety before the assessment was complete. Updated 2024. Accessed July 11, 2024. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=725430&cg_code=&act=view&nPage=4&newsField= .

3. Korea Disease Control and Prevention Agency. The epidemiological investigation did not support a causal relationship between the vaccine and the fatal case. Updated 2024. Accessed July 11, 2024. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=725444&cg_code=&act=view&nPage=4&newsField= .

4. SK Bioscience. SK Bioscience launches chickenpox vaccine ‘SKYVaricella’. Updated 2018. Accessed June 16, 2024. https://www.skbioscience.com/kr/news/news_01_01?mode=view&id=5&page=2&category=content&q=%EC%8A%A4%EC%B9%B4%EC%9D%B4%EB%B0%94 .

5. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1). Updated 2017. Accessed June 16, 2024. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf .

6. Kang HM, Kang KR, Kim YJ, Kang JH, Lee SY. A booster administration of the OKA/SK strain causes fatal disseminated varicella in an immunocompetent child. J Med Virol. 2023; 95(9):e29108. PMID: 37715715.

7. Gershon AA, Gershon MD, Shapiro ED. Live attenuated varicella vaccine: prevention of varicella and of zoster. J Infect Dis. 2021; 224(12):Suppl 2. S387–S397. PMID: 34590140.

8. Merck Sharp & Dohme LLC. Varivax Product Information. Updated 2023. Accessed June 16, 2024. https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax-refrigerated-and-frozen-formulations .

9. Choi UY, Kim KH, Cho HK, Kim DH, Ma SH, Choi YY, et al. Immunogenicity and safety of a newly developed live attenuated varicella vaccine in healthy children: a multi-national, randomized, double-blinded, active-controlled, phase 3 study. Vaccines (Basel). 2023; 11(9):1416. PMID: 37766093.

10. SK Bioscience Business Report System. Updated 2024. Accessed June 16, 2024. https://www.skbioscience.com/kr/ir/notification_02 .

11. Council for International Organizations of Medical Sciences. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Geneva, Swiss: CIOMS;2010.

12. Sadaoka T, Depledge DP, Rajbhandari L, Venkatesan A, Breuer J, Cohen JI. In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency. Proc Natl Acad Sci U S A. 2016; 113(17):E2403–E2412. PMID: 27078099.

13. Ministry of Food and Drug Safety. Post-marketing safety management unified into ‘risk management plan’. Updated 2020. Accessed June 16, 2024. https://www.mfds.go.kr/brd/m_99/view.do?seq=44429&srchFr=&srchTo=&srchWord=%EC%9C%84%ED%95%B4%EC%84%B1&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999&page=2 .

14. SK Bioscience. Approval report for a biological medicinal product (SKYVaricella). Updated 2018. Accessed June 16, 2024. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=201802323aupdateTs2024-05-17%2009:20:08.0b .

15. MSD. Swiss Summary of the Risk Management Plan (RMP) VARIVAX®. Updated 2023. Accessed June 16, 2024. https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/risk-management--psurs--pv-planning-/rmp-summaries.html#varivax .

16. GLAXOSMITHKLINE BIOLOGICALS SA. Summary of the Risk Management Plan for Varilrix. Updated 2023. Accessed June 16, 2024. https://fimea.fi/en/license_holders/pharmacovigilance/summaries_of_risk_management_plans .

17. European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines). Updated 2021. Accessed June 16, 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca .

18. Medical Dictionary for Regulatory Activities. What is MedDRA and how is it used? Updated 2024. Accessed July 14, 2024. https://www.meddra.org/training-materials .

19. European Medicines Agency. Guideline on good pharmacovigilance practices: Annex I - Definitions (Rev. 4). Updated 2017. Accessed June 16, 2024. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp#final-gvp-annex-i-definitions-8712 .

20. Lee J, Seo H, Oh S, Gim H. The comparison of coronavirus disease 2019 vaccine adverse events between Korea and the UK and implications for vaccine adverse event management system. Public Health Wkly Rep. 2024; 17(14):587–613.